Innovating cancer treatments for life

We are shaping the future of oncology for patients

Exelixis CMO, Amy Peterson smiling

2023 Corporate Values and Sustainability Report

Our socially-oriented mission drives our environmental, social and governance program.
Read Our New Report

Exelixis CMO, Amy Peterson smiling

Expanding our oncology pipeline

Discover our newest pipeline asset, XL309, and learn about our partnership with Insilico Medicine.
Read Our News

Woman sitting in front of computer smiling at camera

An exceptional employee experience

Experience more purposeful work and fulfilling opportunities.
See Open Jobs

Male scientist smiling in oncology lab

Accelerating our impact in oncology

Develop next-generation cancer medicines with us.
Let’s Collaborate

Two diverse men talking in hallway

Building a culture of inclusion

Learn about our journey in creating a diverse, collaborative workforce.
Learn More

Supporting our community

We are champions for causes we believe in.
See Our Impact

Inspired by science

Row of test tubes
Row of test tubes
We are innovating at the forefront of cancer care. Our comprehensive approach is powered by a broad array of diverse biotherapeutics and small molecule programs for the treatment of cancer exploring multiple modalities and mechanisms of action.

Leveraging deep expertise in chemistry and biology, as well as strategic partnerships, we are advancing various biotherapeutics that have the potential to become anti-cancer therapies, such as bispecific antibodies, antibody-drug conjugates and other innovative treatments.

Our discovery teams are advancing multiple small molecule programs internally and through collaborations with Aurigene and STORM Therapeutics.

Our R&D programs include next-generation approaches to established targets, as well as opportunities to be first-in-class by applying a range of modalities and mechanisms of action across biologics and small molecules.

Powered by innovation and hope

At Exelixis, cancer is our cause. Throughout nearly three decades, we’ve evolved into a multi-platform cancer company dedicated to creating treatment regimens that challenge the status quo and bring us closer to a cure – all to give more patients hope for the future.

Advancing science for hope

As a diverse, growing team of more than 1,200 people, everyone at Exelixis plays a role in advancing our mission through our innovative drug discovery, development and commercialization efforts. We take pride in our shared purpose, knowing the magnitude of our impact expands with every medicine we create and every form of cancer tumor type we treat.
Collage of colorful<br />
illustrations<br />
depicting stages of<br />
Exelixis growth
Collage of Exelixis<br />
employees<br />
showcasing pride<br />
and unity
“We are Exelixis” sign on white wall
“We are Exelixis” sign on white wall

You are now leaving the website. This link will take you to a website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website.